Revolax Sub-Q Lidocaine 1x1.1ml
Important Notice
Regulated medical device (EU MDR 2017/745). For sale exclusively to qualified healthcare professionals.
What this purchase includes
- Original productFrom the manufacturer or an official distributor, CE marked.
- Batch and expiry documentedRecorded per unit on the delivery note and the invoice.
- Controlled storageOur own Madrid warehouse, 12 to 18 °C under 24 h control.
- Dispatch in 24 to 48 hFrom Madrid, insured and with a tracking number.
- Reachable Monday to Friday9:00 to 17:00 by WhatsApp and email. People, not forms.
REVOLAX™ Sub-Q with lidocaine is the densest gel in the range of monophasic fillers from Across Co., Ltd. (South Korea). It shares with Fine and Deep the concentration of 24 mg/ml of hyaluronic acid, but its degree of cross-linking is the highest in the line: it is designed for deep subcutaneous implantation and for structural augmentation of the cheekbones, chin and mandibular angle, not for the correction of superficial wrinkles.
- Cross-linked HA 24 mg/ml
- Lidocaine 3 mg/ml (0.3 %)
- Contents 1 syringe × 1.1 ml
- Needles 2 × 25G
- Duration 12–18 months
Composition and technology
- Cross-linked hyaluronic acid: 24 mg/ml, of non-animal origin, obtained by bacterial fermentation.
- Lidocaine hydrochloride: 3 mg/ml (0.3 %), to reduce discomfort during injection.
- Cross-linking agent: BDDE. The manufacturer states that residual BDDE is removed by a prolonged dialysis process.
- Monophasic structure with dense, homogeneous cross-linking: the gel is not fractionated into particles of different sizes. Sub-Q has the highest degree of cross-linking in the range, with the greatest capacity for projection and resistance to deformation, and consequently requires the widest needle gauge (25G).
- Manufacturing under ISO 9001 and ISO 13485 certification.
Position within the REVOLAX range
The three variants share the same hyaluronic acid concentration (24 mg/ml) and lidocaine concentration (0.3 %). What differentiates them is the degree of cross-linking and, with it, the density of the gel, the injection plane and the needle gauge supplied.
| Variant | Fine — the most fluid gel |
|---|---|
| Plane | Superficial to mid dermis |
| Needle | 2 × 30G |
| Indication | Fine lines, crow's feet, glabella, perioral and neck wrinkles |
| Duration | 9–12 months |
| Variant | Deep — intermediate density |
|---|---|
| Plane | Mid to deep dermis / superficial subcutaneous |
| Needle | 2 × 27G |
| Indication | Nasolabial sulcus, marionette lines, lips, chin, rhinomodelling |
| Duration | 12–18 months |
| Variant | Sub-Q — the densest gel |
|---|---|
| Plane | Deep subcutaneous |
| Needle | 2 × 25G |
| Indication | Structural augmentation of cheekbones, chin, mandibular angle and nasal dorsum |
| Duration | 12–18 months |
Indications and treatment areas
Injectable hyaluronic acid implant indicated for facial soft tissue augmentation and the correction of deep depressions in adult patients.
- Augmentation and projection of the cheekbones and malar region
- Chin projection
- Definition of the mandibular angle and border
- Augmentation of the nasal dorsum (rhinomodelling)
- Very marked nasolabial sulci and deep depressions
It is not suitable for the correction of superficial wrinkles or for high dermal planes; for those indications REVOLAX Fine or Deep are used.
Technique and treatment protocol
- Injection plane: deep subcutaneous tissue; over bony areas, supraperiosteal plane according to clinical judgement.
- Needles included: 2 units of 25G, sterile and single-use.
- Technique: slow injection with constant pressure. Withdraw the needle while continuing to advance in linear retrograde injection or by fanning technique according to the indication.
- Aspiration prior to injection in accordance with standard clinical protocol to reduce the risk of intravascular injection.
- Manual moulding of the product after injection is recommended in order to even out the distribution.
- Do not apply immediately before or after laser, chemical peeling or dermabrasion.
- Single-use product: discard any product remaining in the syringe after the session.
Technical data
| Manufacturer | Across Co., Ltd. — South Korea |
|---|---|
| Active substance | Cross-linked hyaluronic acid 24 mg/ml, non-animal origin |
| Anaesthetic | Lidocaine HCl 3 mg/ml (0.3 %) |
| Cross-linker | BDDE |
| Structure | Monophasic gel, high cross-linking within the range |
| Presentation | 1 pre-filled syringe of 1.1 ml |
| Needles | 2 × 25G |
| Classification | CE-marked class III medical device |
| Use | Qualified healthcare professionals only |
Storage and pack contents
- Storage: between 2 °C and 25 °C, protected from direct sunlight. Do not freeze.
- Do not use after the expiry date stated on the pack.
- Sterile single-use product. Do not reuse or re-sterilise.
- The pack contains: 1 pre-filled syringe of 1.1 ml, 2 needles 25G, instructions for use and traceability labels.
Contraindications and warnings
Contraindications: pregnancy and breastfeeding; under 18 years of age; known hypersensitivity to hyaluronic acid, to lidocaine or to amide-type local anaesthetics; tendency to hypertrophic or keloid scarring; active skin inflammation or infection in the treatment area (active acne, herpes); active autoimmune disease; porphyria.
Caution: do not apply in areas with pre-existing permanent implants. Avoid simultaneous application with laser, deep chemical peeling or dermabrasion. Assess individually in patients on anticoagulant or antiplatelet therapy and in patients with a history of severe allergic reactions.
Never inject intravascularly. Always consult the instructions for use included in the pack before treatment.
Medical device intended exclusively for qualified healthcare professionals. Technical information based on documentation from the manufacturer Across Co., Ltd. and from the official distribution of the REVOLAX brand. This information sheet does not replace the instructions for use supplied with the product.